The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TTI-621-03: A phase I/II study of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma (LMS).
 
Sant P. Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
 
Ciara Marie Kelly
Employment - Daichii Sankyo (I)
Stock and Other Ownership Interests - daichii sankyo (I)
Consulting or Advisory Role - ChemoCentryx; Exicure; Immunicum; Kartos Therapeutics
Research Funding - AGIOS (Inst); Amgen (Inst); Exicure (Inst); INCYTE (Inst); Kartos Therapeutics (Inst); Merck (Inst); Servier (Inst); xencor (Inst)
 
Erlinda Maria Gordon
Stock and Other Ownership Interests - Counterpoint Biomedica; Delta Next-Gene
Speakers' Bureau - AADi
Research Funding - Bristol Mers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of patents on targeting pharmaceutical agents to injured tissues
 
Doris V. Quon
Honoraria - Bayer; Biomarin; Genentech; Novo Nordisk; Octapharma USA; Sanofi
Consulting or Advisory Role - Bayer; Biomarin; Genentech; Novo Nordisk; Octapharma USA; Sanofi
Speakers' Bureau - Biomarin; Genentech; Novo Nordisk; Sanofi; Takeda
Travel, Accommodations, Expenses - Bayer; Biomarin; Genentech; Novo Nordisk; Octapharma USA; Sanofi; Takeda
 
Ania Moradkhani
No Relationships to Disclose
 
Victoria S. Chua-Alcala
No Relationships to Disclose
 
Theresa M. Thompson
Employment - Pfizer; Trillium Therapeutics
 
Anita Scheuber
Employment - Pfizer; Trillium Therapeutics
 
Ingmar Bruns
Employment - Pfizer; Trillium Therapeutics
 
Victoria E. Allgood
Employment - Pfizer; Trillium Therapeutics
 
Sujana Movva
Consulting or Advisory Role - Genmab
Research Funding - Ascentage Pharma Group (Inst); Hutchison MediPharma (Inst); Trillium Therapeutics (Inst)